Further studies showed that a refined methodology, delivering optimum proportions of P-gp –siRNA–DOX with PEGylated PEI-coated MSNs in an in vivo MDR breast cancer model, showed synergistic tumor growth reduction with considerable P-gp knockdown at heterogeneous tumor locations [50,51,52]. This evidence concerns the gene PGP and breast carcinoma.